Most importantly, we provide evidence in support of innovative therapeutic strategies for the treatment of PCa based on the use of anti-NCL immuno-agents, which can simultaneously accomplish the inhibition of the AR pathway. Here, NUCLEOLIN is linked to posterior cortical atrophy.